Median response duration was 22.3 months (IQR: 10.6–35.7 months) according to overlap-MDS/MPN criteria and 13 months (IQR: 5.8–22.3 months) according to IWG-2006. Paired survival analysis in the 45 ...

So, it’s finally here. MDS 3.0, the updated resident assessment tool, has officially taken effect. So how exactly will this highly anticipated system change the way you, nursing home providers, ...

In PV and ET, MDS risk remains lower than AML risk but increases progressively with advancing attained age. Transformation to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in ...

External validation of the Molecular International Prognostic Scoring System (IPSS-M) for myelodysplastic syndromes.

Advancement of this Phase 3 program, in treatment-naïve higher risk first-line MDS patients, positions rigosertib in an expanded patient population with a more convenient mode of administration 2019 ...

Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials. Background: Although baseline ...